BioGaia AB

Equities

BIOG B

SE0017769995

Pharmaceuticals

Real-time Estimate Cboe Europe 05:13:26 2024-04-25 am EDT 5-day change 1st Jan Change
115.4 SEK +0.79% Intraday chart for BioGaia AB -2.78% +13.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nordic Shares Rose Wednesday; BW LPG Led Increases DJ
Nordic Shares Decreased Thursday; BioGaia Series B Posted Biggest Loss DJ
Nordic Stocks Moved Upward Wednesday; Nordic Semiconductor Climbed Highest DJ
BioGaia AB to Seeks Acquisitions CI
Transcript : BioGaia AB, Q4 2023 Earnings Call, Feb 07, 2024
BioGaia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
BioGaia AB Proposes an Extra Dividend, Payable on May 15, 2024 CI
Biogaia AB Proposes Ordinary Dividend, Payable on May 15, 2024 CI
Transcript : BioGaia AB, Q3 2023 Earnings Call, Oct 20, 2023
BioGaia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BioGaia AB Announces Nomination Committee for the 2024 Annual General Meeting CI
Biogaia AB Provides Preliminarily Earnings Guidance for Third Quarter 2023 CI
Biogaia AB Appoints Theresa Agnew as CEO CI
BioGaia AB Introduces BioGaia Prodentis KIDS in Sweden CI
BioGaia Names New CEO MT
BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023 CI
Transcript : BioGaia AB, Q2 2023 Earnings Call, Jul 21, 2023
BioGaia AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Nordic Shares Moved Upward Wednesday; Storskogen Group Series B Climbed Highest DJ
BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults CI
BioGaia AB Approves Election of Barbro Fridén, Outi Armstrong and Vesa Koskinen as Board Members CI
BioGaia AB Approves Dividend for 2022 CI
BioGaia AB Approves Extra Dividend for 2022 CI
Transcript : BioGaia AB, Q1 2023 Interim Management Statement Call, May 05, 2023
BioGaia AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart BioGaia AB
More charts
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
114.5 SEK
Average target price
140 SEK
Spread / Average Target
+22.27%
Consensus
  1. Stock Market
  2. Equities
  3. BIOG B Stock
  4. News BioGaia AB
  5. BioGaia : Pharma Receives OK for Two Clinical Trials in Sweden, France